|
|
|
|
|
Kidney Cancer Highlights from the 2021 Genitourinary Cancers Symposium |
|
|
|
| The von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment
|
| William Kaelin, MD
|
| William Kaelin provided the keynote lecture entitled “von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment”. Dr. Kaelin discusses the combination of drugs in the management of kidney cancer and several trials in this disease space.
|
|
|
|
|
|
| Patient-Reported Outcomes of Patients with Advanced Renal Cell Carcinoma Treated with First-Line Nivolumab Plus Cabozantinib Versus Sunitinib: the Checkmate-9ER Trial
|
| David Cella, Ph.D.
|
| David Cella presented patient-reported outcomes from the CheckMate-9ER trial of the combination of nivolumab and cabozantinib, as compared to sunitinib, in the first-line treatment of patients with advanced or metastatic renal cell carcinoma.
|
|
|
|
|
|
| Nivolumab + Cabozantinib Versus Sunitinib for Advanced Renal Cell Carcinoma (aRCC): Outcomes by Sarcomatoid Histology and Updated Trial Results with Extended Follow-up of CheckMate-9ER
|
| Robert J. Motzer, MD
|
| Robert Motzer presented updated results of CheckMate-9ER assessing the durability of benefit, as well as assessing outcomes among patients with sarcomatoid features, an aggressive histologic subtype associated with poor prognoses. The data demonstrated, nivolumab and cabozantinib demonstrated improved efficacy and survival outcomes, compared to sunitinib, regardless of the presence of sarcomatoid histology.
|
|
|
|
|
|
| Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma
|
| Toni K. Choueiri, MD
|
| Toni Choueiri presented preliminary results from a phase 2 study of belzutifan (MK-6482) in combination with the FDA-approved multiple TKI, cabozantinib. The study was comprised of two cohorts of patients with advanced clear cell RCC. In Cohort 1, the patients were treatment-naïve; in Cohort 2, patients had previously received immunotherapy and/or TKIs. The focus of the presentation was on preliminary results from Cohort 2. (edited)
|
|
|
|
|
|
| Pathways to Metastatic Colonization in Kidney Cancer
|
| Brandon Manley, MD
|
| In this presentation, Brandon Manley focused on three topics that play a role in the metastatic spread of kidney cancers: EMT transformation, molecular subtypes and how they determine response to therapy, and how host immune cell receptor diversity may impact disease biology and treatment response.
|
|
|
|
|
|
| Pathways to RCC Inception
|
| A. Ari Hakimi, MD
|
| Renal cell carcinoma (RCC) is a diverse group of diseases, as work from multiple recent studies at the genomic and transcriptomic level has highlighted. In this talk, Ari Hakimi discusses what is known about the heterogeneity in pathways to RCC inception, focusing on clear cell RCC.
|
|
|
|
|
|
| Pathways to Detection |
| W. Kimryn Rathmell, MD, Ph.D. |
In this presentation, Kimryn Rathmell first discussed various genetic pathways that have been identified in renal cell carcinoma (RCC) and related these pathways to ongoing work trying to utilize imaging technologies and other noninvasive strategies for improved RCC classification and detection.
|
|
|
|
|
|
| Safety and Efficacy of Nivolumab in Older Patients with Renal Cell Carcinoma: Results of a Sub-Group Analysis of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
|
| Loic Mourey, MD
|
| The NIVOREN GETUG AFU 26 study is a French multicenter prospective study to evaluate the safety and efficacy of nivolumab in a broad “real world setting” in metastatic renal cell carcinoma (mRCC) after failure of 1 or 2 tyrosine kinase inhibitors. Loic Mourey presented results of a subgroup analysis specifically assessing safety and efficacy in older patients.
|
|
|
|
|
|
|
|
|
|
|
| Nivolumab plus Ipilimumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Safety and Efficacy from CheckMate 920 |
| Scott S. Tykodi, MD, Ph.D. |
| At the GU ASCO 2021 annual meeting, Scott Tykodi presented the safety and efficacy results for cohort 2 patients with non-clear cell RCC from CheckMate 920, a patient population with a poor prognosis and without definitive effective treatment. |
|
|
|
|
|
| Phase II Trial of Lenvatinib at Two Starting Doses plus Everolimus in Patients with RCC: Results by Independent Imaging Review and Prior Immune Checkpoint Inhibition |
| Sumanta K. Pal, MD |
| At this year's GU ASCO annual meeting, Sumanta Pal presented results of an exploratory analysis of Study 218, evaluating the efficacy of lenvatinib 14 mg versus lenvatinib 18 mg, both in combination with everolimus 5 mg, per independent imaging review assessment and by prior immune checkpoint inhibitor status per investigator assessment. |
|
|
|
|
|
| Gene Expression Profiling to Identify Metabolic Gene Signature Predictive of Recurrence After Surgery In Stage III Clear-Cell RCC |
| Shuchi Gulati, MD |
| Shuchi Gulati presented results of an analysis pertaining to genes involved in metabolic reprogramming in kidney cancer. The aim of the study was to analyze metabolic signatures in primary tumors from patients that remain disease free versus those that recur within 24 months of surgery. |
|
|
|
|
|
| Therapy-Relevant Gene Signatures In The High Risk Localized Renal Cell Carcinoma Setting: Transcriptomic Data From Patients Receiving Placebo On A Randomized Phase III Trial (PROTECT) |
| Phillip Rappold, MD, Ph.D. |
| Phillip Rappold sought to interrogate prognostic gene expression in the tumor microenvironment from patients with localized disease. Given the early data fueling interest in developing the prognostic capacity of these gene signatures in the metastatic space, and their ability to predict outcomes in the post-nephrectomy setting, these biologically relevant subgroups should be explored as a guide for future biomarker-driven adjuvant therapy trials. |
|
|
|
|
|
|
|
| To view our full coverage of the 2021 ASCO GU Symposium, visit the Conference Coverage section on UroToday.com
|
|
|
|
|
|
|
 |
|
|
|
|
